Inmar and Premier Renew Pact on Critical Reverse Logistics Services

WINSTON-SALEM, NC – February 19, 2026 – Inmar Intelligence and Premier, Inc. have renewed a national group purchasing agreement for Pharmacy Reverse Distribution Services, reinforcing a long-standing partnership that underscores the critical, though often overlooked, role of managing returned pharmaceuticals. The agreement, effective February 1, 2026, ensures that Premier’s vast network of healthcare members can continue accessing pre-negotiated terms for services essential to navigating the financial and regulatory complexities of modern pharmacy operations.

While the announcement signifies a continued business relationship, its implications reach deep into the operational core of thousands of pharmacies. This renewal highlights a growing recognition that reverse distribution—the process of managing returned, expired, recalled, and overstocked pharmaceuticals—is no longer a simple logistical task but a strategic imperative for financial health, regulatory adherence, and patient safety.

The Unseen Engine of Pharmacy Operations

In an era of escalating cost pressures and an increasingly dense web of regulations, pharmacy reverse distribution has evolved into a vital function. The global market for these services, valued at nearly $6.5 billion in 2024, is projected to surge to over $9.4 billion by 2031. This growth is fueled by the sheer volume of products that must be efficiently removed from the supply chain, a process that involves recovering financial credit, ensuring compliance, and handling disposal.

For pharmacies, from large hospital systems to local retailers, managing this process internally is a monumental challenge. It requires expertise in navigating manufacturer return policies, tracking inventory, and adhering to strict federal and state laws. Failure to do so can result in lost revenue from unrecovered credits, fines for non-compliance, and significant operational risks.

This is the intricate landscape where companies like Inmar Intelligence operate. By providing an integrated solution that combines returns, recalls, compliance, and disposal, they offer a streamlined pathway through this complexity. The renewed agreement with Premier, a leading healthcare improvement company, validates the importance of outsourcing this function to specialized experts.

"Premier members continue to choose Inmar because of the scale, reliability and value we deliver across their pharmacy operations," said Anthony Garcia, Vice President, Healthcare Sales at Inmar Intelligence. "This is a direct reflection of the trust placed in our ability to recover value, maintain regulatory compliance, improve performance and simplify increasingly complex workflows."

A Strategic Alliance in a Competitive Market

The partnership leverages the strengths of both organizations. Premier, Inc., which reported revenues of $1.34 billion in fiscal 2024, functions as a powerful Group Purchasing Organization (GPO). It unites thousands of providers to negotiate favorable contracts for everything from medical supplies to complex services, enabling members to achieve cost savings and efficiencies they could not attain alone.

Inmar Intelligence, meanwhile, brings over 45 years of experience and a sharp focus on the healthcare supply chain, a commitment recently underscored by its divestiture of other business units to concentrate on its healthcare and technology divisions. The company serves over 50,000 pharmacies and touts a 99% processing accuracy rate. Its core offering is a vertically integrated, "one-touch" reverse distribution model designed to accelerate credit recovery and reduce handling, which in turn minimizes errors and costs.

This market is not without competition. Firms like PharmaLink, which bolstered its market position by acquiring Stericycle’s reverse distribution division, also promise comprehensive compliance and credit recovery. In this environment, long-term partnerships and proven reliability become key differentiators. The continuation of the Inmar-Premier agreement suggests that Inmar's integrated model and track record have provided tangible value to Premier’s members over the years.

Navigating a Labyrinth of Regulations

The most compelling driver for specialized reverse distribution services is the formidable regulatory environment. Pharmacies must contend with a host of agencies, each with its own stringent rules.

The Drug Enforcement Administration (DEA) mandates a rigorous process for handling controlled substances, requiring that they be rendered "non-retrievable" to prevent diversion. This necessitates the use of licensed Reverse Distributors and meticulous record-keeping, including DEA Form 41 for destruction.

Simultaneously, the Food and Drug Administration (FDA) is tightening its grip on supply chain integrity. The Drug Supply Chain Security Act (DSCSA) now requires full, package-level electronic tracing, with immediate suspension for non-compliance. Furthermore, with FDA drug recalls and warning letters on the rise, a proposed 24-hour recall execution mandate looms, making a pre-approved, efficient reverse logistics plan a necessity, not a choice. The Environmental Protection Agency (EPA) also weighs in, regulating pharmaceutical waste under the Resource Conservation and Recovery Act (RCRA) to prevent environmental contamination.

For a healthcare provider, navigating this tripartite regulatory structure is a full-time job. The Inmar-Premier agreement provides a pre-vetted solution, offering what Garcia calls the ability to operate with "clarity and confidence" in an environment where the penalties for error are severe.

Beyond the Bottom Line: Protecting Patients and the Planet

While financial recovery and operational efficiency are the immediate benefits of effective reverse distribution, the broader impact extends to public health and environmental stewardship. A well-oiled reverse logistics system is the primary defense against patient harm from recalled drugs. When a product is flagged for a safety issue, the ability to quickly and accurately remove it from pharmacy shelves across the nation is paramount.

Likewise, the responsible disposal of billions of dollars' worth of expired and unused pharmaceuticals is a critical environmental concern. Simply discarding these products can lead to the contamination of water supplies and ecosystems. Compliant reverse distribution ensures that hazardous materials are incinerated or neutralized according to EPA and DEA standards, mitigating the environmental footprint of the healthcare industry.

Ultimately, the renewed pact between Inmar Intelligence and Premier, Inc. is more than a standard business contract. It is a reflection of the healthcare industry’s increasing reliance on specialized partners to manage the complex and high-stakes process of pharmaceutical returns. By ensuring continued access to these services, the agreement helps fortify the financial stability, regulatory integrity, and safety of the nation's pharmacies.